Week of March 28, 2022 | Vol. 11, Issue 13
Events Hosted or Attended by Bourne Partners
May 17-19, 2022 - Philadelphia, PA
May 24-26, 2022 - New York City, NY
April 23-26, 2022 - Palm Beach, FL
June 13-16, 2022 - San Diego, CA
August 27-29, 2022 - Boston, MA
October 2022 - Charlotte, NC
Recent Transactions, Trading Comps, Market Reports, M&A Pipeline
An Overview of Transactions Within Market Sub-segments
Below are summaries and charts with the past week's transactions from the different healthcare sectors. For a detailed table showing data for each industry transaction click on any of the charts. Total transaction values are provided in USD millions.
A Breakdown of Relevant Trading Multiples
This is a high-level breakdown of median revenue and EBITDA multiples for each of the specific sub sectors.

For a complete trading comp analysis (including the individual equities that comprise the sub sectors), click on the table. 

Note: data reflects prior week close.
Insight Into Healthcare Related Industries
Representative Current Retained Sell-Side And Partnering Opportunities
Project Focus
Sell-side | CMO | Liquids and Semi-solids CMO headquartered in North America

Project Nucleus
Buy-side| CDMO | North American radiopharmaceutical company
Project Power Play
Buy-side | Specialty Pharma | In-license and acquire approved Rx products including legacy brands, generics, and niche launch-ready products

Project Trident
Buy-side | Generic Pharma | Manufacturing liquid generics
A Sampling of Industry Headlines From Last Week
Ever since last year's annual American Association of Cancer Research (AACR) meeting, Volastra's phone has been "ringing off the hook," according to CEO Charles Hugh-Jones, M.D.
Three big players in kidney care—Fresenius Health Partners, Cricket Health, and InterWell Health—plan to form a new value-based care company focused on services for the earlier stages of kidney disease.
A new study found that over the last decade, rural counties that had a hospital shut its doors had a higher share of Black and Hispanic residents and greater shares of income inequality compared to prior decades.
With a new CEO and a phase 2 trial ready to go, Ocelot Bio has snagged $36 million in a series A financing led by RA Capital Management, Venrock and Vivo Capital.

The work of TannerGAP includes addressing medicine market withdrawal, post-clinical trial solutions, mitigating drug shortages and managing medicine supply on a Named Patient basis. Learn more from TannerGAP EVP, Maryori Alvarenga.

When demand for PPE and testing kits surged to unparalleled levels in March 2020 during the first wave of Covid-19, Tanner had to do something to help. Learn more about the development of TannerGMS (global medical supplies) and the future of medical supplies and diagnostics here.

The Tanner team will be attending several networking events in the coming weeks. Let’s connect to discuss how our organizations can improve patient lives, together.